The purpose of the trial is to determine whether NXT007 works at least as well as Emicizumab in preventing bleeds. Participants receive regular injections for several months and attend scheduled visits where doctors check their health, collect blood samples, and ask about daily activities and quality of life. The main way the study measures success is by counting the average number of bleeding episodes that need treatment each year, called the annualized number of treated bleeds.

Throughout the study, safety is closely watched. Researchers look for any side effects such as reactions at the injection site, allergic responses, or signs of clotting problems. Participants also complete simple questionnaires about how their condition affects everyday life, helping to assess both the medical and personal impact of the treatments.

In the study, participants receive one booster dose of the vaccine in the muscle. The study then follows how the body responds over the next days after the booster. Blood samples are taken during the study to check for signs of protection, and any side effects such as pain, redness, swelling, headache, fever, or tiredness are recorded. The study compares the three earlier vaccination plans to see which one gives a strong response after the booster.

In this study, participants are assigned to one of the treatment groups by chance. One group receives tirabrutinib alone, and the other group receives rituximab plus temozolomide. Treatment is given over a period of time with regular study visits, and health is checked throughout the study to see how the disease responds and how long the disease stays under control. The study also looks at overall survival, which means how long people live after joining the study, and at changes in steroid medicine use.

This is a Phase 3 study, which means the treatment is being compared in a larger group of people to help show how well it works and how safe it is. It is a randomized study, so the treatment group is chosen by chance, and it is open-label, which means both the study team and the participants know which treatment is being given.

In the study, one group receives letrozole together with the usual fertility treatment, while the other group receives the usual treatment without letrozole. Treatment is given during one egg collection cycle, and any embryos made from that cycle may be transferred fresh or frozen and used later within about one year. The study then follows the pregnancy outcomes after these embryo transfers. The study also looks at related conditions such as adenomyosis, a condition in which tissue similar to the lining of the womb grows into the womb muscle.

The study is designed to see whether letrozole can improve reproductive results in this setting and to collect information on pregnancy, birth, and any problems that may happen during pregnancy. It also records pain after egg collection and quality of life around the time of embryo transfer.

The trial will compare the effects of Belimumab to a placebo, in addition to the standard treatments that participants are already receiving for their condition. Participants will receive either Belimumab or a placebo through injections over a period of 52 weeks. The main goal is to see if Belimumab can help maintain lung volume better than the placebo. Throughout the study, participants will be monitored for changes in their lung function and overall health.

Participants in the study will be adults who have been diagnosed with ILD associated with CTD, such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), or other similar conditions. The study aims to provide more information on whether Belimumab can be a beneficial addition to the current treatment options for these lung diseases. The trial will also track any side effects or health changes experienced by participants during the study period.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

People in the study will receive either VMX-C001 or the usual care used for this situation. Some participants may also receive heparin, another blood-thinning medicine, if planned by the treating team. The study is designed to compare the two approaches during the procedure and shortly afterward, without changing the urgent care needed for the surgery or procedure.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

The main goal of the trial is to find out whether the study drug is safe and can improve the symptoms of Rett syndrome. Participants are randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers know which one is being given. The treatment period lasts about three months, during which caregivers and clinicians complete questionnaires about behavior, sleep, and communication, and routine heart checks are performed. After the initial phase, participants may continue in an open‑label extension where all receive the active medication, allowing further observation of long‑term safety and benefit.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of this research is to determine how well ruxolitinib cream works in treating moderate atopic dermatitis in young patients. During the study, participants will apply either ruxolitinib cream or the vehicle cream to affected areas of their skin, excluding the scalp. The treatment period lasts for 8 weeks, followed by an extended observation period.

The study will monitor changes in skin condition, including improvements in rash coverage, intensity of itching, and overall disease severity. Blood samples will be collected from some participants to measure how much of the medication enters the bloodstream. The research will also track any side effects that may occur during the treatment period.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.

The purpose of the study is to compare how well the combination of zanzalintinib and pembrolizumab works against using pembrolizumab alone in treating this type of cancer. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. Some participants may receive a placebo, which looks like the real medication but does not contain the active drug. The study will involve regular check-ups and monitoring to assess the treatment’s effects and any side effects experienced by the participants.

The study will take place over several months, with participants receiving treatment and being monitored for changes in their condition. The goal is to determine if the combination of zanzalintinib and pembrolizumab can improve outcomes for patients with this type of cancer. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to gather important data on the treatment’s effectiveness.

People in the study receive zigakibart during the extension period, which means treatment continues after the earlier trial has ended. The study follows participants over time to see how they do with ongoing treatment and to collect information about side effects, blood and urine test results, and other health checks. It also looks at how the body handles the medicine and whether the immune system makes proteins that react to it.

Because this is a long-term extension study, the main focus is continued treatment and follow-up rather than changing between different medicines. The study is designed to gather more safety information while participants remain on zigakibart.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The purpose of the study is to assess how effective ATRA and tailored radiotherapy are in treating patients with localized squamous cell carcinoma of the head and neck. Participants in the study will receive either standard or reduced-target volume radiotherapy, with or without ATRA. The study will also involve the use of other medications, including cetuximab and cisplatin, which are commonly used in cancer treatment. Cetuximab is a protein-based medication, while cisplatin is a chemical compound used to stop the growth of cancer cells.

Throughout the study, participants will receive treatments over a period of time and will be monitored for their response to the therapy. The study aims to understand the impact of these treatments on the survival and quality of life of patients, as well as any potential side effects. The ultimate goal is to improve treatment strategies for head and neck cancer, providing better outcomes for patients.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of this study is to look at how safe it is for people with haemophilia A to switch from emicizumab to Mim8. The study will observe what happens during the time when emicizumab is leaving the body while people are starting treatment with Mim8. This includes watching for any unwanted effects that might occur during this switch.

During the study, participants will receive Mim8 injections under the skin for up to 26 weeks. They will need to attend regular visits and keep track of their experiences using an electronic diary. The study will also ask participants to complete questionnaires about how they find using the injection device and how the treatment affects their daily life. The study involves adults and adolescents aged 12 years and older who have been taking emicizumab for at least 8 weeks and who have decided with their doctor to stop taking emicizumab.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The treatment will be administered in the form of tablets taken orally, and the study will last for a period of up to 48 weeks.

Throughout the study, participants will be monitored to assess the effectiveness and safety of Povorcitinib. The main goal is to see if there is a significant improvement in the itchiness and appearance of the skin lesions by the end of the study period. Participants will have regular check-ups to track their progress and any changes in their condition.

Participants in the study will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The treatment period will last up to 24 weeks, during which participants will take the medication orally. The study will monitor the participants’ skin condition and overall health to assess the effectiveness and safety of the treatments. The goal is to determine if ESK-001 can significantly improve the symptoms of plaque psoriasis compared to the placebo and to evaluate its performance against Otezla.

The study is designed to provide valuable information about the potential benefits of ESK-001 for treating moderate to severe plaque psoriasis. By comparing it with a placebo and an existing treatment, researchers hope to understand how well ESK-001 works and its safety profile. This information could help in developing new treatment options for people living with this skin condition.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, as measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The study aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

Participants in the study will receive Batoclimab through a subcutaneous injection, which means it is injected under the skin. The treatment will be administered once a week for a total of 24 weeks. For the first 12 weeks, participants will receive a dose of 680 mg, followed by a reduced dose of 340 mg for the remaining 12 weeks. Some participants will receive a placebo, which looks like the treatment but does not contain the active substance.

The study aims to observe changes in the condition of the eyes, specifically looking at the reduction in eye protrusion, known as proptosis, by the end of the 24-week period. The trial will also monitor other aspects of the disease, such as changes in eye inflammation and overall eye health. The goal is to determine if Batoclimab can effectively improve symptoms of TED compared to the placebo.

The purpose of the study is to determine how well Ruxolitinib cream works in treating Prurigo Nodularis. Participants in the study will be randomly assigned to receive either the Ruxolitinib cream or a vehicle cream, which looks and feels like the Ruxolitinib cream but does not contain the active medication. This helps researchers compare the effects of the actual medication against a cream without the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the Ruxolitinib cream and who is receiving the vehicle cream, to ensure unbiased results.

Throughout the study, participants will apply the cream to their skin as directed and attend regular check-ups to monitor their progress. The study will last for several weeks, with key assessments at different points to evaluate improvements in symptoms. The main goal is to see if there is a significant reduction in itchiness and skin lesions after using the Ruxolitinib cream compared to the vehicle cream. Participants’ experiences and any changes in their condition will be carefully recorded to help determine the treatment’s effectiveness and safety.

Participants in the study will receive a combination of medications. One group will take RO7771950 along with trastuzumab and capecitabine. The other group will receive tucatinib combined with trastuzumab and capecitabine. The trastuzumab may be given through an IV infusion, which is a liquid medicine delivered directly into a vein, or as a subcutaneous injection, which is administered just under the skin. The other medications are taken as an oral tablet by mouth.

During the study, medical professionals will monitor how the treatments affect the cancer and how the body responds over time. The research will look at how long the cancer stays stable without growing, a measure known as progression-free survival. Other aspects of the study include monitoring overall survival, how much the tumors shrink, and any side effects experienced during the treatment period.

The goal of the study is to see how pegtibatinase affects levels of total homocysteine (tHcy) and methionine (Met) in the blood. High levels of these substances are common in people with this disease. During the study, blood samples will be taken to monitor these levels and to ensure that the treatment is being tolerated well by the body.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is divided into two phases. In the first phase, the focus is on determining the appropriate dose of Elacestrant when combined with Abemaciclib. In the second phase, the study aims to evaluate how effective this combination is in treating patients with brain metastases from this type of breast cancer. Participants will take the medications orally, and the study will monitor their response to the treatment over time.

Throughout the study, participants will be observed for any changes in their condition, including the size and number of brain metastases. The study will also track any side effects or adverse reactions to the medications. The goal is to gather information that could help improve treatment options for patients with this type of breast cancer in the future.

The purpose of this study is to find out if xaluritamig can help people live longer compared to the other treatment options. Xaluritamig is given as an infusion into a vein, which means it is delivered directly into the bloodstream through a needle. Some people in the study may also receive siltuximab, which is another medicine given through a vein that may help manage certain side effects. The study will also look at whether the cancer stops growing or shrinking, how long any improvements last, whether bone problems are delayed, and how the treatments affect pain and quality of life. Additionally, the study will monitor any unwanted effects or side effects that occur during treatment and will measure how the body processes xaluritamig and whether the body develops any immune response to it.

People joining this study will be randomly assigned to receive either xaluritamig or one of the other treatment options chosen by their doctor. Throughout the study, participants will have regular check-ups that include scans to see how the cancer is responding, blood tests to check overall health and levels of a substance called prostate-specific antigen, and questionnaires to understand how they are feeling and how the treatment is affecting their daily life. The study will continue for several years to gather enough information about how well the treatments work and how safe they are.

During the study, patients will receive TUB-040 along with standard chemotherapy drugs. The medication is designed to target specific features of cancer cells. Doctors will monitor patients closely to check for any unwanted effects or side effects that may occur during treatment. Blood tests and other medical evaluations will be done regularly to check how the body is responding to the treatment and to measure the levels of the medication in the blood. Scans will be performed to see if the tumors are getting smaller or if the cancer is staying stable. The study will also collect tumor tissue samples to examine certain markers in the cancer cells that might help predict how well the treatment will work.

The study will measure several outcomes including the number and severity of side effects that patients experience, how the medication moves through the body, and whether the body develops an immune response to the medication. Doctors will also assess how many patients respond to the treatment, how long it takes for the cancer to respond, how long the response lasts, and how long patients live without their cancer getting worse. Additional measurements will include changes in a blood marker called CA-125, which is often used to monitor ovarian cancer. Patients who join this study will have already received previous treatments for their ovarian cancer and their cancer will have come back or progressed after earlier therapy.

The purpose of the study is to learn about the long-term safety of Mim8 when used as a preventive treatment in people with haemophilia A, whether or not they have inhibitors. The study will look at what side effects occur over time and how well the treatment works to prevent bleeding episodes. Participants joining this study are already taking part in or have completed other research studies with Mim8, and this study allows them to continue receiving the treatment for a longer period. Some very young participants who have not yet received much treatment for haemophilia A may also join the study.

During the study, participants will receive regular injections of Mim8 under the skin for up to 262 weeks, which is about five years. Throughout this time, they will attend regular clinic visits where doctors will check their health, take blood samples to measure the level of medication in the blood and look for any antibodies the body might make against the treatment, and ask about any bleeding episodes or side effects. Participants or their caregivers will keep a diary to record any bleeding episodes, treatments used, and any problems with the injection device. The study will also look at how easy the injection device is to use for those participants who use it.

Participants in this study will be randomly assigned to receive either ivonescimab or bevacizumab, both given in combination with FOLFOX chemotherapy. The study is designed so that neither the participants nor their doctors will know which treatment is being given, which helps ensure fair comparison of the results. The medications will be given through a vein, which means they are delivered directly into the bloodstream through an intravenous line. During the study, participants will have regular check-ups where doctors will monitor the size of tumors using imaging scans and assess how well the treatment is working. The study will also track any side effects that occur and measure the levels of ivonescimab in the blood at different times.

The study will also collect information about how long participants live overall, how many people respond to treatment, and how long those responses last. Doctors will monitor for any unwanted effects from the medications and check blood tests for abnormal results. For those receiving ivonescimab, the study will also check whether the body develops antibodies against this medication, which could affect how well it works. This study is intended for people who have not yet received treatment for their metastatic colorectal cancer, though previous treatment for earlier stages of the disease is allowed if it was completed more than twelve months before the cancer spread.

During the study, participants will take VX-407 for up to 52 weeks. The main focus is to measure changes in the total size of the kidneys using a type of scan called MRI, which takes detailed pictures of the inside of the body. The study will check if the medication can slow down or stop the growth of the kidneys compared to the beginning of the study. Doctors will also watch for any side effects and will regularly check blood tests, heart tracings using a test called ECG, and other health measurements to make sure the medication is safe.

Before joining the study, participants will have a special genetic test done using a device that looks for specific changes in the PKD1 gene. This test uses a blood sample and looks for particular types of genetic changes that are not the kind that completely stop the gene from working. Only people with these specific genetic changes and who have kidneys of a certain size based on the MRI scan will be included in the study.